As advances are made in patient tumor characterization and toward a complete understanding of the complex networks influenced by p53 mutation, therapies activating RCD pathways may yet pave the way for the next generation of efficacious precision medicines for p53-mutant cancers. The gene discussed is TP53; the disease is neoplasm.